Does Rallies show Form 4 insider transactions for TOVX?

Yes. Rallies tracks TOVX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TOVX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TOVX. It does not provide personalized investment advice.

TOVX (Theriva Biologics, Inc.) Stock Analysis - Insider Trades

Theriva Biologics, Inc. (TOVX) is a publicly traded Healthcare sector company. As of May 21, 2026, TOVX trades at $0.30 with a market cap of $13.54M and a P/E ratio of -0.14. TOVX moved +11.05% today. Year to date, TOVX is +24.48%; over the trailing twelve months it is -31.22%. Its 52-week range spans $0.16 to $2.64. Analyst consensus is buy with an average price target of $2.50. Rallies surfaces TOVX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TOVX stock inside the company?

Recent TOVX insider activity includes SHALLCROSS STEVEN A bought 14.00K, SHALLCROSS STEVEN A bought 26.00K, SHALLCROSS STEVEN A bought 25.00K, SHALLCROSS STEVEN A bought 25.00K, and SHALLCROSS STEVEN A bought 25.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TOVX Key Metrics

Key financial metrics for TOVX
Metric	Value
Price	$0.30
Market Cap	$13.54M
P/E Ratio	-0.14
EPS	$-2.08
Dividend Yield	0.05%
52-Week High	$2.64
52-Week Low	$0.16
Volume	181.95K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-23.74M
Gross Margin	0.00%

Recent TOVX Insider Trades

SHALLCROSS STEVEN A bought 14.00K (~$9.70K) on Jun 7, 2023.
SHALLCROSS STEVEN A bought 26.00K (~$16.45K) on Jun 6, 2023.
SHALLCROSS STEVEN A bought 25.00K (~$26.07K) on Feb 10, 2023.
SHALLCROSS STEVEN A bought 25.00K (~$23.51K) on Feb 2, 2023.
SHALLCROSS STEVEN A bought 25.00K (~$21.82K) on Jan 25, 2023.

Latest TOVX News

Theriva Biologics Posts $2M Q1 Loss, $14.4M Cash and FDA Aligns on Phase 3 — May 5, 2026
Theriva Biologics Secures $38M SYN-020 License, Boosts Cash to $15.2M, Plans Phase 3 PDAC Trial — Mar 12, 2026

TOVX Analyst Consensus

2 analysts cover TOVX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.50.

Common questions about TOVX

Who is trading TOVX stock inside the company?: Recent TOVX insider activity includes SHALLCROSS STEVEN A bought 14.00K, SHALLCROSS STEVEN A bought 26.00K, SHALLCROSS STEVEN A bought 25.00K, SHALLCROSS STEVEN A bought 25.00K, and SHALLCROSS STEVEN A bought 25.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TOVX?: Yes. Rallies tracks TOVX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TOVX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TOVX. It does not provide personalized investment advice.